Polycystic ovary syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: Intaking120 grams per day of low-fat yogurt containing vitamin D (with a dose of 1000 IU or 25 micrograms) and vitamin E (with a dose of 50 IU or 34 mg) and two pro
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Willingness to cooperate in the study and provide written consent Being in the reproductive age range of 18-45 years Diagnosis of polycystic ovary syndrome based on the Rotterdam criteria No intake of alcohol or drugs Not pregnant or breastfeeding No menopause No participate in other research studies
Exclusion criteria
Exclusion criteria: Using drugs affecting blood pressure, blood lipids, ovarian function, insulin sensitivity (including metformin, incretin, and Thiazolidinediones) and oral contraceptives (including progesterone and estrogen) since 3 months before entering the study. Taking any nutritional supplements for 3 months before entering the study Taking drugs affecting vitamin D metabolism having diabetes, thyroid disease or any systemic disease (such as kidney, liver, digestive system, cardiovascular system) Having disorders that lead to an increase in androgens in the blood (such as Cushing's syndrome, hyperprolactinemia)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Homeostasis model assessment of insulin resistance. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention). Method of measurement: Formula. | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention). Method of measurement: Scale.;Body Mass Index. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention). Method of measurement: Formula.;Waist Circumference. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention). Method of measurement: Stadiometer.;Hip Circumference. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention). Method of measurement: Stadiometer.;Waist to Hip Ratio. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention). Method of measurement: Formula.;Systolic Blood Pressure. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention). Method of measurement: Electronic Sphygmomanometer.;Diastolic Blood Pressure. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention). Method of measurement: Electronic Sphygmomanometer.;Fasting Blood Sugar. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention). Method of measurement: Pars Azmoon Kit.;Fasting Insulin. Timepoint: At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention). Method of measurement: ELISA Kit.;The Quantitative Insulin Sensitivity Check Index. Timepoint: At the beginning of the st | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMoein Askarpour
Shiraz University of Medical Sciences
Outcome results
None listed